# US 2024/0343692 A1 · Selective psychedelic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0343692 A1
- Document ID: US20240343692A1
- Status: Published application
- Kind: A1
- Application number: 18/682,031
- Filed: 2022-06-21
- Published: 2024-10-17
- Earliest claimed: 2021-08-09
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Peter Wipf; Nikhil R. Tasker; Ethan J. Pazur
- Web page: https://patentgrep.com/patent/US20240343692A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 221/22: Bridged ring systems
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/30: for treating abuse or dependence
- C07D 221/18: Ring systems of four or more rings
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 457/02: with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
- C07D 457/04: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D 471/18: Bridged systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound, or a pharmaceutically acceptable salt thereof, of formula I: wherein R1, R8, R9, R31, R32, R33, and R34 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl; and R2, R4, R5, R6, and R7 are each independently H, F, Cl, Br, —OR1—NR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, of formula I:
wherein R1, R8, R9, R31, R32, R33, and R34 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl; and
R2, R4, R5, R6, and R7 are each independently H, F, Cl, Br, —OR1, —NR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R8 and R9 are each independently C1-C6 alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein at least one of R4, R5, R6, and R7 is F, Cl, or Br, and the remaining R4, R5, R6, and R7 are each H.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is N-heteroaryl-substituted C1-C6 alkyl.

### Claim 5

A compound, or a pharmaceutically acceptable salt thereof, of formula II:
wherein R1, R8, R9, R31, R32, R33, and R34 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl; and
R2, R4, R5, R6, and R7 are each independently H, F, Cl, Br, —OR1, —NR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R8 and R9 are each independently C1-C6 alkyl.

### Claim 7 (depends on 5)

The compound of claim 5, wherein at least one of R4, R5, R6, and R7 is F, Cl, or Br, and the remaining R4, R5, R6, and R7 are each H.

### Claim 8 (depends on 5)

The compound of claim 5, wherein R1 is N-heteroaryl-substituted C1-C6 alkyl.

### Claim 9

A compound, or a pharmaceutically acceptable salts thereof, of formula III:
wherein R1 and R8 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl;
R2, R5, R6, R7, R41, R93, R94, R95, and R96 are each independently H, F, Cl, Br, —OR1, —NR8R9, —CR1R1OR1, —CO2R1, —CONR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl;
R9, R31, R32, R33, R91, and R92 are each independently H, —CR1R1OR1, —CO2R1, —CONR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl; and
where each bond represented by is a single or double bond as needed to satisfy valence requirements, and where each of R41, R95, R94, and R91 may or may not be present as needed to satisfy valency requirements.

### Claim 10 (depends on 9)

The compound of claim 9, wherein the compound is of formula IIIa

### Claim 11 (depends on 9)

The compound of claim 9, wherein the compound is of formula IIIb

### Claim 12 (depends on 9)

The compound of claim 9, wherein the compound is of formula IIIc

### Claim 13 (depends on 9)

The compound of claim 9. wherein the compound is of formula IIId

### Claim 14 (depends on 9)

The compound of claim 9, wherein R8 is methyl.

### Claim 15 (depends on 9)

The compound of claim 9, wherein R93 is —CR1R1OR1, wherein each R1 is H.

### Claim 16 (depends on 9)

The compound of claim 9, wherein each of R1, R2, R5, R6, R7, R31, R32 and R33 is H.

### Claim 17

A compound, or a pharmaceutically acceptable salt thereof, of formula IV:
wherein R1 and R8 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl;
R2, R5, R6, R7, R93, and R95 are each independently H, F, Cl, Br, —OR1, —NR8R9, —CR1R1OR1, —CO2R1, —CONR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl; and
R9, R31, R32, R33, R91, and R92 are each independently H, —CR1R1OR1, —CO2R1, —CONR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R8 is methyl.

### Claim 19

A compound, or a pharmaceutically acceptable salt thereof, of formula V:
wherein R1 and R8 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl;
R2, R5, R6, R7, R41, R93, R94 and R95 are each independently H, F, Cl, Br, —OR1, —NR8R9, —CR1R1OR1, —CO2R1, —CONR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl;
R9, R31, R32, R33, R91, and R92 are each independently H, —CR1R1OR1, —CO2R1, —CONR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl; and
where each bond represented by is a single or double bond as needed to satisfy valence requirements, and where each of R94 and R91 may or may not be present as needed to satisfy valency requirements.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R8 is methyl.

### Claim 21 (depends on 19)

The compound of claim 19, wherein R93 is —CONR8R9, wherein R8 and R9 are each C1-C6 alkyl, and R94 is H.

### Claim 22 (depends on 1)

A method for improving the well-being of a subject, comprising administering a therapeutically effective amount of a compound of claim 1 to the subject in need thereof.

### Claim 23 (depends on 1)

A method for treating a neurological condition in a subject, comprising administering a therapeutically effective amount of a compound of claim 1 to the subject in need thereof.
